


FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1696R1	Serial No. 09/442,898	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Aguet, M.		
				Filing Date 18 Nov 1999	Group To Be Assigned	
						
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials		Document Number	Date	Name	Class	Filing Date
GN	1	5,635,177	03.06.97	Bennett et al.		
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>						
GN	2	Andres et al., "Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis" <u>Oncogene</u> 9:1461-1467 (1994)				
GN	3	Bennett et al., "Cloning and Characterization of HTK, a Novel Transmembrane Tyrosine Kinase of the EPH Subfamily" <u>Journal of Biological Chemistry</u> 269(19):14211-14218 (1994)				
GN	4	Bennett et al., "Molecular Cloning of a Ligand for the EPH-Related Receptor Protein-Tyrosine Kinase Htk" <u>Proc. Natl. Acad. Sci. USA</u> 92:1866-1870 (1995)				
GN	5	Bergemann et al., "ELF-2, a New Member of the Eph Ligand Family, Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites" <u>Molecular &amp; Cellular Biology</u> 15(9):4921-4929 (1995)				
GN	6	Bruckner et al., "Tyrosine phosphorylation of transmembrane ligands for eph receptors" <u>Science</u> 275:1640-1643 (Mar 14, 1997)				
GN	7	Carmeliet et al., "Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele" <u>Nature</u> 380(6573):435-438 (Apr 4, 1996)				
GN	8	Clossek et al., "Cloning, characterization, and differential expression of MDK2 and MDK5, two novel receptor tyrosine kinases of the eck.eph family" <u>Oncogene</u> 11(10):2085-2095 (Nov 16, 1995)				
GN	9	Clapp et al., "The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis" <u>Endocrinology</u> 133(3):1292-1299 (Sep 1993)				
GN	10	Daniel et al., "ELK and LERK-2 in developing kidney and microvascular endothelial assembly" <u>Kidney International</u> 50(Suppl. 57):S-73 - S-81 (1996)				
GN	11	Davis et al., "Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning" <u>Cell</u> 87(7):1161-1169 (Dec 27, 1996)				
GN	12	Dumont et al., "Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo" <u>Genes &amp; Development</u> 8(16):1897-1909 (Aug 15, 1994)				
GN	13	Ferrara et al., "Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene" <u>Nature</u> 380(6573):439-442 (Apr 4, 1996)				
GN	14	Folkman and D'Amore, "Blood vessel formation: what is its molecular basis?" <u>Cell</u> 87(7):1153-1155 (Dec 27, 1996)				
GN	15	Folkman and Shing, "Angiogenesis" <u>Journal of Biological Chemistry</u> 267:10931-10934 (1992)				
GN	16	Fong et al., "Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium" <u>Nature</u> 376:66-70 (1995)				
GN	17	Garner, A., "Vascular Diseases" <u>Pathobiology of Ocular Disease. A Dynamic Approach</u> , Garner, A., Klintworth, GK, Eds., 2nd edition, NY:Marcel Dekker pps. 1625-1710 (1994)				
GN	18	Good et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin" <u>Proc. Natl. Acad. Sci. USA</u> 87(17):6624-6628 (Sep 1990)				
GN	19	Hanahan, D., "Signaling vascular morphogenesis and maintenance" <u>Science</u> 277:48-50 (1997)				
Examiner	Garfinkel			Date Considered 3/05/01		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1626F1	Serial No. 09/442,898
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Aguet, M.	
				Filing Date 18 Nov 1999	Group To Be Assigned
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
GN	20	Holland et al., "Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands" <u>Nature</u> 383(6612):722-725 (Oct 24, 1996)			
GN	21	Horak et al., "Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer" <u>Lancet</u> 340(8828):1120-1124 (Nov 7, 1992)			
GN	22	Inada et al., "Selective expression of the receptor tyrosine kinase, HTK, on human erythroid progenitor cells" <u>Blood</u> 89(8):2757-2765 (Apr 15, 1997)			
GN	23	Flaegsbrun and D'Amore, "Regulators of angiogenesis" <u>Ann. Rev. Physiol.</u> 53:217-239 (1991)			
GN	24	Macchiarini et al., "Relation of neovascularisation to metastasis of non-small-cell lung cancer" <u>Lancet</u> 340(8812):145-146 (Jul 18, 1992)			
GN	25	Maisonpierre et al., "Angiopoietin-2, a Natural Antagonist for Tie2 that Disrupts in vivo Angiogenesis" <u>Science</u> 277 55-60 (Jul 4, 1997)			
GN	26	Nikolova et al., "Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis" <u>Journal of Cell Science</u> 111(Pt 13):2741-2751 (Sep 1993)			
GN	27	O'Reilly et al., "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma" <u>Cell</u> 79(2):315-328 (Oct 21, 1994)			
GN	28	O'Reilly et al., "Endostatin: an endogenous inhibitor of angiogenesis and tumor growth" <u>Cell</u> 83(2) 277-285 (Jan 24, 1997)			
GN	29	Orioli and Klein, "The Eph receptor family: axonal guidance by contact repulsion" <u>Trends in Genetics</u> 13(9) 354-359 (Sep 1997)			
GN	30	Pandey et al., "Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF- $\alpha$ -induced angiogenesis" <u>Science</u> 268(5210):567-569 (Apr 23, 1995)			
GN	31	Pasquale, E., "The Eph family of receptors" <u>Current Opinion in Cell Biology</u> 9(5):608-615 (Oct 1997)			
GN	32	Feis et al., "Mice devoid of interferon regulatory factor 1 (IRF-1) show normal expression of type I interferon genes" <u>EMBO Journal</u> 13(20):4798-4806 (Oct 17, 1994)			
GN	33	Reynolds et al., "Angiogenesis in the female reproductive system" <u>FASEB J.</u> 6:886-892 (1992)			
GN	34	Fisau et al., "Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies" <u>Development</u> 102:471-473 (1988)			
GN	35	Fisau, W., "Mechanisms of angiogenesis" <u>Nature</u> 386(6626):671-674 (Apr 17, 1997)			
GN	36	Sato et al., "Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation" <u>Nature</u> 376(6535):70-74 (Jul 6, 1995)			
GN	37	Schlaeger et al., "Vascular endothelial cell lineage-specific promoter in transgenic mice" <u>Development</u> 121(4):1089-1098 (Apr 1995)			
GN	38	Shalaby et al., "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice" <u>Nature</u> 376:62-66 (1995)			
GN	39	Spencer et al., "The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor" <u>Journal of Experimental Medicine</u> 187(4):571-578 (Feb 16, 1998)			
Examiner <i>Goufanti</i>				Date Considered 03/05/01	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Att'y Docket No.


P1696R1

Serial No.

09/442.898

### LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



Applicant

Aguet, M.

Filing Date

18 Nov 1999

Group	Mean	SD	95% CI	95% CI	95% CI
1	1.00	0.00	1.00	1.00	1.00
2	1.00	0.00	1.00	1.00	1.00
3	1.00	0.00	1.00	1.00	1.00
4	1.00	0.00	1.00	1.00	1.00
5	1.00	0.00	1.00	1.00	1.00
6	1.00	0.00	1.00	1.00	1.00
7	1.00	0.00	1.00	1.00	1.00
8	1.00	0.00	1.00	1.00	1.00
9	1.00	0.00	1.00	1.00	1.00
10	1.00	0.00	1.00	1.00	1.00
11	1.00	0.00	1.00	1.00	1.00
12	1.00	0.00	1.00	1.00	1.00
13	1.00	0.00	1.00	1.00	1.00
14	1.00	0.00	1.00	1.00	1.00
15	1.00	0.00	1.00	1.00	1.00
16	1.00	0.00	1.00	1.00	1.00
17	1.00	0.00	1.00	1.00	1.00
18	1.00	0.00	1.00	1.00	1.00
19	1.00	0.00	1.00	1.00	1.00
20	1.00	0.00	1.00	1.00	1.00
21	1.00	0.00	1.00	1.00	1.00
22	1.00	0.00	1.00	1.00	1.00
23	1.00	0.00	1.00	1.00	1.00
24	1.00	0.00	1.00	1.00	1.00
25	1.00	0.00	1.00	1.00	1.00
26	1.00	0.00	1.00	1.00	1.00
27	1.00	0.00	1.00	1.00	1.00
28	1.00	0.00	1.00	1.00	1.00
29	1.00	0.00	1.00	1.00	1.00
30	1.00	0.00	1.00	1.00	1.00
31	1.00	0.00	1.00	1.00	1.00
32	1.00	0.00	1.00	1.00	1.00
33	1.00	0.00	1.00	1.00	1.00
34	1.00	0.00	1.00	1.00	1.00
35	1.00	0.00	1.00	1.00	1.00
36	1.00	0.00	1.00	1.00	1.00
37	1.00	0.00	1.00	1.00	1.00
38	1.00	0.00	1.00	1.00	1.00
39	1.00	0.00	1.00	1.00	1.00
40	1.00	0.00	1.00	1.00	1.00
41	1.00	0.00	1.00	1.00	1.00
42	1.00	0.00	1.00	1.00	1.00
43	1.00	0.00	1.00	1.00	1.00
44	1.00	0.00	1.00	1.00	1.00
45	1.00	0.00	1.00	1.00	1.00
46	1.00	0.00	1.00	1.00	1.00
47	1.00	0.00	1.00	1.00	1.00
48	1.00	0.00	1.00	1.00	1.00
49	1.00	0.00	1.00	1.00	1.00
50	1.00	0.00	1.00	1.00	1.00
51	1.00	0.00	1.00	1.00	1.00
52	1.00	0.00	1.00	1.00	1.00
53	1.00	0.00	1.00	1.00	1.00
54	1.00	0.00	1.00	1.00	1.00
55	1.00	0.00	1.00	1.00	1.00
56	1.00	0.00	1.00	1.00	1.00
57	1.00	0.00	1.00	1.00	1.00
58	1.00	0.00	1.00	1.00	1.00
59	1.00	0.00	1.00	1.00	1.00
60	1.00	0.00	1.00	1.00	1.00
61	1.00	0.00	1.00	1.00	1.00
62	1.00	0.00	1.00	1.00	1.00

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Gaußmutter

Date Considered

considered			
03	05	01	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce  
Patent and Trademark Office

P1696R1

09/442,898

(Use several sheets if necessary)

Aguet, M.

18 Nov 1999

To Be Assigned

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
GW	47	WO 00/24413	04.05.00	PCT				
	48	WO 97/48804	24.12.97	PCT				
	49	WO 99/52541	21.10.99	PCT				

[illegible]

Garbhueto

3/05/01

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.